Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 9:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 155 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Intracerebral Hemorrhage
Interventions
NXY-059
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
64
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 61 more
Conditions
Narcolepsy Type 2
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Redwood City, California + 29 more
Completed Phase 2 Interventional Results available

Clarithromycin for the Treatment of Hypersomnia

NCT01146600
Conditions
Hypersomnia, Idiopathic Hypersomnia, Narcolepsy
Interventions
Clarithromycin followed by placebo, Placebo then Clarithromycin
Drug
Lead sponsor
Lynn Marie Trotti
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Not applicable Interventional

Narcolepsy Nightmare Study

NCT05709873
Conditions
Narcolepsy, Narcolepsy Type 1, Narcolepsy With Cataplexy, Narcolepsy Type 2, Narcolepsy Without Cataplexy
Interventions
Imagery rehearsal therapy, Targeted dream control
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder

NCT04788953
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol Oral Tablet, Placebo
Drug
Lead sponsor
Charles A. Czeisler, PhD, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum
Interventions
Solriamfetol 150 mg Oral Tablet
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Conditions
Idiopathic Hypersomnia
Interventions
Serdexmethylphenidate, Placebo
Drug · Other
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
41
States / cities
Birmingham, Alabama • Daphne, Alabama • Guntersville, Alabama + 34 more
Conditions
Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
43
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 37 more
Conditions
Narcolepsy With Cataplexy
Interventions
JZP-258, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
12
States / cities
Orange, California • Stanford, California • Boulder, Colorado + 9 more
Conditions
Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Completed Not applicable Interventional Accepts healthy volunteers

Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease

NCT01742182
Conditions
Parkinson's Disease
Interventions
Light exposure
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
Web-based psychoeducational resource
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Narcolepsy
Interventions
Not listed
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more
Completed No phase listed Observational Accepts healthy volunteers

Body Weight Regulation in Patients With Narcolepsy

NCT00283894
Conditions
Narcolepsy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Narcolepsy
Interventions
JNJ-17216498, Modafinil
Drug
Lead sponsor
Alza Corporation, DE, USA
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Conditions
Narcolepsy
Interventions
sodium oxybate
Drug
Lead sponsor
Orphan Medical
Industry
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
37
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 31 more
Conditions
Narcolepsy
Interventions
Armodafinil
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 18 more
Conditions
Shift Work
Interventions
No-nap, 15-min nap, 30-min nap, 45-min nap, 60-min nap
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 32 more
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ORX750
Drug
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
19
States / cities
Auburn, Alabama • Santa Ana, California • Miami, Florida + 14 more
Conditions
Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke, Ischemic Attack, Transient
Interventions
NXY-059
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 95 more
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Boulder, Colorado • Brandon, Florida + 12 more
Conditions
Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
Interventions
BTD-001, Placebo
Drug
Lead sponsor
Balance Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more
Conditions
Schizophrenia
Interventions
Modafinil, Placebo
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California